Opioid Prescribing: Safe Practice, Changing Lives (2.5 CME)

Horizontal Logo.jpg

The misuse of extended-release and long-acting (ER/LA) opioids is a major public health problem. Centers for Disease Control and Prevention reported the following:

  • From 2000 to 2015 more than half a million people died from drug overdoses.
  • 91 Americans die every day from an opioid overdose.

The CO*RE/ASAM Opioid Prescribing: Safe Practice, Changing Lives course addresses the opioid public health crisis. This comprehensive course was developed by renowned experts from Collaborative for REMS Education (CO*RE) and incorporates all six units outlined in FDA blueprint for safe opioid prescribing. The updated course also provides necessary context for safe opioid prescribing by discussing biopsychosocial aspects of pain, the newest clinical guidelines on the treatment of chronic pain, and state policies about prescribing opioids.

Learners will be able to:

  • Accurately assess patients with pain for consideration of an opioid trial
  • Establish realistic goals for pain management and restoration of function
  • Initiate opioid treatment (IR and ER/LA) safely and judiciously, maximizing efficacy while minimizing risks
  • Monitor and re-evaluate treatment continuously; discontinue safely when appropriate
  • Counsel patients and caregivers about use, misuse, abuse, diversion, and overdose
  • Educate patients about safe storage and disposal of opioids
  • Demonstrate working knowledge and ability to access general and specific information about opioids, especially those used in your practice.

Edwin A. Salsitz

MD, DFASAM

Dr. Edwin A. Salsitz has been an attending physician at Mount Sinai Beth Israel, Department of Psychiatry and Behavioral Sciences, since 1983, and is an Assistant Professor of Medicine at the Icahn School of Medicine at Mount Sinai.  He is the principal investigator of the Methadone Medical Maintenance (office-based methadone maintenance) research project.  Dr. Salsitz is certified by the American Board of Addiction Medicine (ABAM), as well as by the Board of Internal Medicine and Pulmonary Disease.  He  lectures frequently and has been published on a variety of addiction medicine topics.

Dr. Salsitz is a course director for ASAM sponsored buprenorphine trainings, and is a mentor in the PCSS-MAT and PCSS-O mentoring programs. He has co-chaired  the ASAM Review Course, the ASAM Common Threads Course, the ASAM State of the Art Course and  is a reviewer for the Journal of Addiction Medicine. Currently Dr. Salsitz is the chair of the ASAM REMS ER/LA Opioids committee. Dr. Salsitz is a member of the ASAM CME committee and Chair of the New York Society of Addiction Medicine CME and Education committee. He is the recipient of the 2014 ASAM Annual AwardDr. Salsitz is a member of the Medical Advisory Panel, for the New York State Office of Alcohol and Substance Abuse Services.

Kirk Moberg

MD, PhD, FASAM

Dr. Moberg has served as medical director of three addiction recovery centers, currently the Illinois Institute for Addiction Recovery in Peoria, IL. He also serves as Clinical Professor in the departments of Internal Medicine and Psychiatry & Behavioral Medicine at UICOM. He holds extensive accomplishments in managing healthcare quality and outcomes; implementing performance improvement and project management methods; managing hospital, medical group, and managed care operations. He is certified by the American Board of Internal Medicine, the American Board of Addiction Medicine and the Certifying Commission for Medical Management.

He is a member of the board of the Illinois Society of Addiction Medicine and the National Rural Association for Alcohol and Drug Abuse, Inc. Dr. Moberg also serves on the Advisory Committee of the Illinois Professional Health Program.

CME Information and Disclosure Listing

The American Society of Addiction Medicine (ASAM) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The American Society of Addiction Medicine designates this enduring material for a maximum of 2.5 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This course has been designated as an approved CME Activity by the American Board of Addiction Medicine (ABAM). Physicians enrolled in the ABAM Maintenance of Certification (MOC) Program can apply a maximum of 2.5 AMA PRA Category 1 Creditsto the CME requirement for Part II: Lifelong Learning and Self-Assessment.

In accordance with the disclosure policies of ASAM and the ACCME, the effort is made to ensure balance, independence, objectivity, and scientific rigor in all educational activities. These policies include resolving all conflicts of interest between the CME Committee, Planning Committee and faculty, and commercial interests that might otherwise compromise the goal and educational integrity of this activity. All CME Committee, Planning Committee and faculty participating in the activity have disclosed all relevant financial relationships with commercial interests. The CME Committee has reviewed these disclosures and determined that the planning committee and faculty relationships are not inappropriate in the content of their respective presentations and are not inconsistent with the educational goals and integrity of the activity.

ASAM CME Committee

Name

Nature of Relevant Financial Relationship

Commercial Interest

What was received?

For what role?

Adam J. Gordon, MD, MPH, FACP, DFASAM

None

Catherine Friedman, MD

None

Noel Ilogu, MD, MRCP None

Herbert Malinoff, MD, FACP, DFASAM

None

Edwin A. Salsitz, MD, DFASAM

None

John Tanner, DO, DFASAM

Reckitt

Astra Zeneca

Pfizer

Alkermes

Honorarium

Honorarium

Honorarium

Honorarium

Speaker

Speaker

Speaker

Speaker

Program Planning Committee

Name

Nature of Relevant Financial Relationship

Commercial Interest

What was received?

For what role?

Herbert Malinoff, MD, FACP, DFASAM

None

Yngvild Olsen, MD, MPH

None

Theodore Parran, MD

None

Edwin Salsitz, MD, DFASAM

None

R. Corey Waller, MD, MS, FACEP, DFASAM

None


Course Faculty

Name

Nature of Relevant Financial Relationship

Commercial Interest

What was received?

For what role?

Edwin Salsitz, MD, DFASAM

None

Kirk Moberg, MD, PhD, FASAMNone

ASAM CME Committee Reviewers

Name

Nature of Relevant Financial Relationship

Commercial Interest

What was received?

For what role?

Jacob Bobrowski, MD, FAAFP

None

Anthony H. Dekker, DO, DFASAM

None

Acknowledgement

Presented by ASAM, a member of the Collaborative on REMS Education (CO*RE), 10 interdisciplinary organizations working together to improve pain management and prevent adverse outcomes.

RPC Commercial Support Disclosure Statement

This educational activity is supported by an independent educational grant from the ER/LA Opioid Analgesic REMS Program Companies. Please see this link for a listing of the member companies. This activity is intended to be fully compliant with the ER/LA Opioid Analgesic REMS education requirements issued by the US Food & Drug Administration.

This course is not intended to advocate for the use of ER/LA Opioids, but to ensure proper education about safe prescribing practices should a medical provider determine that ER/LA Opioids are the best course of treatment.

Key:

Complete
Failed
Available
Locked
Course Recording
Open to view video.
Open to view video. Recorded on Wednesday, July 26, 2017.
Specific Drug Information for ER/LA Products
Open to download resource.
Open to download resource. Review general and specific drug information for ER/LA Opioid analgesic products.
Test
14 Questions
14 Questions Test
Course Evaluation
13 Questions
13 Questions Course Evaluation
Credit
Up to 2.50 medical credits available  |  Certificate available
Up to 2.50 medical credits available  |  Certificate available 2.5 Credits